PLX4032 and GSK260641436 were administered to athymic nude mice orally once daily for 20–22 days starting 14- or 17-days after transplantation of the BRAFi-resistant melanoma cells with impaired PTEN, Sk-mel28R, or WLH6215R, by subcutaneous injection. Here, PTEN is linked to melanoma.